The antibiotic polymyxin can pierce the armor of active bacteria, but are ineffective when armor production is shut off in dormant bacteria.
PMB-CT01, a BAFF-R targeting CAR-T cell therapy, achieved a 100% complete response rate in relapsed/refractory follicular lymphoma patients. The phase 1 PMB-102 study focuses on safety, optimal dosing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback